Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

doi:10.1158/2159-8290.CD-16-0040

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Cancer discovery - 1 Jun 2016

Teachey David T, Lacey Simon F, Shaw Pamela A, Melenhorst J Joseph, Maude Shannon L, Frey Noelle, Pequignot Edward, Gonzalez Vanessa E, Chen Fang, Finklestein Jeffrey, Barrett David M, Weiss Scott L, Fitzgerald Julie C, Berg Robert A, Aplenc Richard, Callahan Colleen, Rheingold Susan R, Zheng Zhaohui, Rose-John Stefan, White Jason C, Nazimuddin Farzana, Wertheim Gerald, Levine Bruce L, June Carl H, Porter David L, Grupp Stephan A

Abstract excerpt

UNLABELLED: Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, CD19

Share to Cell- and Tissue-Based Therapy

Share to Immunotherapy

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Receptors, Antigen, T-Cell

Share to ROC Curve

Share to Severity of Illness Index

Source

Open in PubMed Open full text

Identifiers

PMID: 27076371
DOI: 10.1158/2159-8290.CD-16-0040
PMCID: PMC5448406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.PMID 27076371Read ↗

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read ↗

Pre-infusion plasma proteomics identifies an endothelial–immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphomaSemantic proximity Read ↗

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytesSemantic proximity Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

Early induction of cytokine release syndrome by rapidly generated CAR T cells in a preclinical mouse modelSemantic proximity Read ↗

Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in SwedenSemantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.Semantic proximity Read ↗

Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Further modification of the EASIX score through the addition of phosphorous and IL-6 improves prediction of CRS and ICANS after CAR-T therapySemantic proximity Read ↗

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.